Corrigendum to "The amyloid-beta degradation pattern in plasma-A possible tool for clinical trials in Alzheimer's disease" [Neurosci. Lett. 573 (2014) 7-12] DOI: 10.1016/j.neulet.2014.04.041;The amyloid-β degradation pattern in plasma-A possible tool for clinical trials in Alzheimer's disease

Neuroscience Letters

Volumn 573, Issue , 2014, Pages 7-12

  Pannee, Josef ^a   Törnqvist, Ulrika ^a   Westerlund, Anni ^a   Ingelsson, Martin ^b   Lannfelt, Lars ^b   Brinkmalm, Gunnar ^a   Persson, Rita ^a   Gobom, Johan ^a   Svensson, Johan ^a,c   Johansson, Per ^a,d   Zetterberg, Henrik ^a,e   Blennow, Kaj ^a   Portelius, Erik ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c CENTRAL HOSPITAL   (Sweden)

^d Department of Neuropsychiatry Skaraborg Central Hospital   (Sweden)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Alzheimer's disease; Amyloid beta; Immunoprecipitation; Mass spectrometry; Plasma

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-38]; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; UNCLASSIFIED DRUG; AMYLOID BETA-PROTEIN (1-38); AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT;

AGED; ALZHEIMER DISEASE; ANALYTIC METHOD; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOPRECIPITATION; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PILOT STUDY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN PROCESSING; QUADRUPOLE MASS SPECTROMETRY; SELECTED REACTION MONITORING; BLOOD; CASE CONTROL STUDY; VERY ELDERLY;

AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; PEPTIDE FRAGMENTS; PILOT PROJECTS;

EID: 84901296246     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2015.05.042     Document Type: Erratum

References (27)

1. Bibl M., Welge V., Esselmann H., Wiltfang J. Stability of amyloid-beta peptides in plasma and serum. Electrophoresis 2012, 33:445-450.
2. Black R.S., Sperling R.A., Safirstein B., Motter R.N., Pallay A., Nichols A., Grundman M. A single ascending dose study of bapineuzumab in patients with Alzheimer disease. Alzheimer Dis. Assoc. Disord. 2010, 24:198-203.
3. Blennow K., de Leon M.J., Zetterberg H. Alzheimer's disease. Lancet 2006, 368:387-403.
4. Blennow K., Hampel H., Weiner M., Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat. Rev. Neurol. 2010, 6:131-144.
5. Brinkmalm G., Portelius E., Ohrfelt A., Mattsson N., Persson R., Gustavsson M.K., Vite C.H., Gobom J., Mansson J.E., Nilsson J., Halim A., Larson G., Ruetschi U., Zetterberg H., Blennow K., Brinkmalm A. An online nano-LC-ESI-FTICR-MS method for comprehensive characterization of endogenous fragments from amyloid beta and amyloid precursor protein in human and cat cerebrospinal fluid. J. Mass Spectrom. 2012, 47:591-603.
6. Ditto N.T., Kline T.R., Alfinito P.D., Slemmon J.R. Enrichment and analysis of Alzheimer's Abeta1-42 peptide in human plasma and whole blood. J. Neurosci. Methods 2009, 182:260-265.
7. Farlow M., Arnold S.E., van Dyck C.H., Aisen P.S., Snider B.J., Porsteinsson A.P., Friedrich S., Dean R.A., Gonzales C., Sethuraman G., DeMattos R.B., Mohs R., Paul S.M., Siemers E.R. Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. Alzheimer's Dementia 2012, 8:261-271.
8. Fleisher A.S., Raman R., Siemers E.R., Becerra L., Clark C.M., Dean R.A., Farlow M.R., Galvin J.E., Peskind E.R., Quinn J.F., Sherzai A., Sowell B.B., Aisen P.S., Thal L.J. Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch. Neurol. 2008, 65:1031-1038.
9. Hansson O., Zetterberg H., Vanmechelen E., Vanderstichele H., Andreasson U., Londos E., Wallin A., Minthon L., Blennow K. Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiol. Aging 2010, 31:357-367.
10. Hu S., Loo J.A., Wong D.T. Human body fluid proteome analysis. Proteomics 2006, 6:6326-6353.
11. Kaneko N., Yamamoto R., Sato T.A., Tanaka K. Identification and quantification of amyloid beta-related peptides in human plasma using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Proc. Jpn. Acad., Ser. B: Phys. Biol. Sci. 2014, 90:104-117.
12. Kang J.H., Korecka M., Toledo J.B., Trojanowski J.Q., Shaw L.M. Clinical utility and analytical challenges in measurement of cerebrospinal fluid amyloid-beta(1-42) and tau proteins as Alzheimer disease biomarkers. Clin. Chem. 2013, 59:903-916.
13. Kuo Y.M., Kokjohn T.A., Watson M.D., Woods A.S., Cotter R.J., Sue L.I., Kalback W.M., Emmerling M.R., Beach T.G., Roher A.E. Elevated abeta42 in skeletal muscle of Alzheimer disease patients suggests peripheral alterations of AbetaPP metabolism. Am. J. Pathol. 2000, 156:797-805.
14. Landau S.M., Lu M., Joshi A.D., Pontecorvo M., Mintun M.A., Trojanowski J.Q., Shaw L.M., Jagust W.J., Alzheimer's Disease Neuroimaging Initiative Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β-amyloid. Ann. Neurol. 2013, 74:826-836.
15. Le Bastard N., Aerts L., Leurs J., Blomme W., De Deyn P.P., Engelborghs S. No correlation between time-linked plasma and CSF Abeta levels. Neurochem. Int. 2009, 55:820-825.
16. Li Q.X., Whyte S., Tanner J.E., Evin G., Beyreuther K., Masters C.L. Secretion of Alzheimer's disease Abeta amyloid peptide by activated human platelets. Lab. Invest. 1998, 78:461-469.
17. Mattsson N., Rajendran L., Zetterberg H., Gustavsson M., Andreasson U., Olsson M., Brinkmalm G., Lundkvist J., Jacobson L.H., Perrot L., Neumann U., Borghys H., Mercken M., Dhuyvetter D., Jeppsson F., Blennow K., Portelius E. BACE1 inhibition induces a specific cerebrospinal fluid beta-amyloid pattern that identifies drug effects in the central nervous system. PLoS One 2012, 7:e31084.
18. May P.C., Dean R.A., Lowe S.L., Martenyi F., Sheehan S.M., Boggs L.N., Monk S.A., Mathes B.M., Mergott D.J., Watson B.M., Stout S.L., Timm D.E., Smith Labell E., Gonzales C.R., Nakano M., Jhee S.S., Yen M., Ereshefsky L., Lindstrom T.D., Calligaro D.O., Cocke P.J., Greg Hall D., Friedrich S., Citron M., Audia J.E. Robust central reduction of amyloid-beta in humans with an orally available, non-peptidic beta-secretase inhibitor. J. Neurosci. 2011, 31:16507-16516.
19. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984, 34:939-944.
20. Nalivaeva N.N., Turner A.J. The amyloid precursor protein: a biochemical enigma in brain development, function and disease. FEBS Lett. 2013, 587:2046-2054.
21. Pannee J., Portelius E., Oppermann M., Atkins A., Hornshaw M., Zegers I., Hojrup P., Minthon L., Hansson O., Zetterberg H., Blennow K., Gobom J. A selected reaction monitoring (SRM)-based method for absolute quantification of Abeta38, Abeta40, and Abeta42 in cerebrospinal fluid of Alzheimer's disease patients and healthy controls. J. Alzheimer's Dis. 2013, 33:1021-1032.
22. Portelius E., Brinkmalm G., Tran A.J., Zetterberg H., Westman-Brinkmalm A., Blennow K. Identification of novel APP/Abeta isoforms in human cerebrospinal fluid. Neurodegener. Dis. 2009, 6:87-94.
23. Portelius E., Mattsson N., Andreasson U., Blennow K., Zetterberg H. Novel abeta isoforms in Alzheimer's disease-their role in diagnosis and treatment. Curr. Pharm. Des. 2011, 17:2594-2602.
24. Portelius E., Tran A.J., Andreasson U., Persson R., Brinkmalm G., Zetterberg H., Blennow K., Westman-Brinkmalm A. Characterization of amyloid beta peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry. J. Proteome Res. 2007, 6:4433-4439.
25. Rissman R.A., Trojanowski J.Q., Shaw L.M., Aisen P.S. Longitudinal plasma amyloid beta as a biomarker of Alzheimer's disease. J. Neural Transm. 2012, 119:843-850.
26. Roepstorff P., Fohlman J. Proposal for a common nomenclature for sequence ions in mass spectra of peptides. Biomed. Mass Spectrom. 1984, 11:601.
27. Roher A.E., Esh C.L., Kokjohn T.A., Castano E.M., Van Vickle G.D., Kalback W.M., Patton R.L., Luehrs D.C., Daugs I.D., Kuo Y.M., Emmerling M.R., Soares H., Quinn J.F., Kaye J., Connor D.J., Silverberg N.B., Adler C.H., Seward J.D., Beach T.G., Sabbagh M.N. Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease. Alzheimer's Dementia 2009, 5.